Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Crespo J, et al. Among authors: fernandez i. Clin Gastroenterol Hepatol. 2017 Jun;15(6):945-949.e1. doi: 10.1016/j.cgh.2017.02.020. Epub 2017 Feb 24. Clin Gastroenterol Hepatol. 2017. PMID: 28238958
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Fernández-Rodríguez CM, et al. Among authors: fernandez i. Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700116
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Colombo M, Strasser S, Moreno C, Abrao Ferreira P, Urbanek P, Fernández I, Abdurakmonov D, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Lonjon-Domanec I, Wedemeyer H. Colombo M, et al. Among authors: fernandez i. J Hepatol. 2014 Nov;61(5):976-83. doi: 10.1016/j.jhep.2014.06.005. Epub 2014 Jun 16. J Hepatol. 2014. PMID: 24946280 Clinical Trial.
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marenco S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Forns X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL; Italian and Spanish (IAS)-BoC Study Group. Bruno S, et al. J Viral Hepat. 2015 May;22(5):469-80. doi: 10.1111/jvh.12342. Epub 2014 Oct 14. J Viral Hepat. 2015. PMID: 25311757 Free article.
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL; en representación del grupo de investigadores del estudio LEAD-IN. Crespo J, et al. Among authors: fernandez i. Gastroenterol Hepatol. 2015 Nov;38(9):517-24. doi: 10.1016/j.gastrohep.2015.04.002. Epub 2015 May 12. Gastroenterol Hepatol. 2015. PMID: 25976446 Spanish.
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
Crespo J, Diago M, Cabezas J, Berenguer M, Broquetas T, Serra MÁ, Morillas R, García-Samaniego J, Calleja JL, Sánchez JJ, Lens S, Soto-Fernández S, Sacristán B, Fernández I, López-Núñez C, Buti M, Romero-Gómez M, Sáez-Royuela F, Fernández C, Jorquera F, Sánchez-Antolín G, Pascasio JM, Cuadrado A, Hernández-Guerra M. Crespo J, et al. Among authors: fernandez c, fernandez i. Ann Hepatol. 2015 Jul-Aug;14(4):477-86. Ann Hepatol. 2015. PMID: 26019034 Free article.
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.
Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fernández I, Buti M, Millán R, Romero-Gómez M. Ampuero J, et al. Among authors: fernandez i. J Clin Virol. 2015 Jul;68:56-60. doi: 10.1016/j.jcv.2015.05.010. Epub 2015 May 14. J Clin Virol. 2015. PMID: 26071337
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Ferreira PA, Strasser SI, Urbanek P, Mangia A, Calleja JL, Iraqi W, DeMasi R, Lonjon-Domanec I, Moreno C, Wedemeyer H. Lepida A, et al. Among authors: fernandez i. PLoS One. 2015 Sep 23;10(9):e0138503. doi: 10.1371/journal.pone.0138503. eCollection 2015. PLoS One. 2015. PMID: 26398503 Free PMC article. Clinical Trial.
1,725 results